In summary, combined detection of sCD23, sCD27, and sCD30 offers promising potential for ultra-early risk stratification in HIV-NHL, while sCD163 may serve as a specific diagnostic marker for EBV-driven subtypes, particularly PCNSL. Here, CD163 is linked to non-Hodgkin lymphoma.